In B-cell lymphoma models, combining Venetoclax with CD19 CAR-T cells significantly enhanced tumor cell apoptosis and improved CAR-T cell persistence, demonstrating its potential clinical application for patients harboring BCL-2-expressing leukemia and lymphoma (28). Here, CD19 is linked to B-cell non-Hodgkin lymphoma.